Relationship between lipoprotein(a) phenotypes and albumin excretion rate in non-insulin-dependent diabetes mellitus: Protective effect of 'null' phenotype?

European Journal of Clinical Investigation

Volumn 27, Issue 6, 1997, Pages 497-502

  Hernandez C ^a   Simo R ^a   Chacon P ^a   Segarra, A ^a   Lopez D ^a   Mesa, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Albumin excretion rate; Diabetic nephropathy; Lipoprotein(a); Lipoprotein(a) phenotype; Non insulin dependent diabetes mellitus

Indexed keywords

ALBUMIN; LIPOPROTEIN A;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TRANSPORT;

EID: 0030811721     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1997.1420684.x     Document Type: Article

References (54)

1. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Lancet 1988;ii:530-3.
2. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as a predictor of increased mortality in elderly people. BMJ 1990;300:297-300.
3. Haffner SM, Stern MP, Gruber KK, Hazuda HP, Mitchell BD, Patterson JK. Microalbuminuria: potential marker for increased cardiovascular risk factors in non-diabetic subjects? Arteriosclerosis 1990;10:727-31.
4. Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U, Murrells TJ. Microalbuminuria predicts mortality in non-insulin-dependent diabetes. Diabetic Med 1984;1:17-19.
5. Mattock MB, Keen H, Viberti GC et al. Coronary heart disease and urinary albumin secretion rate in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1988;31:82-7.
6. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Eight to nine year mortality in known non-insulin dependent diabetics and controls. Kidney Int 1992;41:731-5.
7. Rhoads GC, Dahlén G, Berg K, Morton NE, Dannenberg AL. Lp (a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986;256:2540-4.
8. Rosegren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ 1990;301:1248-51.
9. Sandholzer CH, Boerwinkle E, Saha N, Tong C, Utermann G. Apolipoprotein (a) phenotypes, Lp (a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo (a) gene in coronary heart disease. J Clin Invest 1992;89:1040-6.
10. Velho G, Erlich D, Turpin E et al. Lipoprotein (a) in diabetic patients and normoglycemic relatives in familial NIDDM. Diabetes Care 1993;16:742-7.
11. Ruiz J, Thillet J, Huby T et al. Association of elevated lipoprotein (a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein (a) phenotypes. Diabetologia 1994;37: 585-91.
12. O'Brien T, Chu B, Nguyen TT et al. Lipids and Lp (a) lipoprotein levels and coronary artery disease in subjects with non-insulin-dependent diabetes mellitus. Mayo Clin Proc 1994;69:430-5.
13. Hiraga T, Kobayashi T, Okubo M et al. Prospective study of lipoprotein (a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care 1995;18:241-4.
14. Haffner SM, Gruber KK, Morales PA et al. Lipoprotein (a) concentrations in Mexican Americans and non-hispanic whites: the San Antonio heart study. Am J Epidemiol 1992;136:1060-8.
15. Jenkins AJ, Steele JS, Janus ED, Santamaria JD, Best JD. Plasma apolipoprotein (a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1992;35: 1055-9.
16. Nielsen FS, Voldsgaard AI, Gall MA, Rossing P, Hommel E, Andersen P. Apolipoprotein (a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy. Diabetologia 1993;36:438-44.
17. Heller FR, Jamart J, Honore P et al. Serum lipoprotein (a) in patients with diabetes mellitus. Diabetes Care 1993;16:819-23.
18. Jerums G, Allen TJ, Tsalamandris C et al. Relationship of progressively increasing albuminuria to apoprotein (a) and blood pressure in type 2 (non-insulin-dependent) and type 1 (inslin-dependent) diabetic patients. Diabetologia 1993;36:1037-44.
19. Gruden G, Veglio M, Cavallo-Perin P et al. Lipoprotein (a) in non-insulin-dependent diabetic patients with normo- and microalbuminuria. Horm Metab Res 1994;26:489-90.
20. Scnack C, Pietschmann P, Knöbl P, Schuller E, Prager R, Schernthaner G. Apolipoprotein (a) levels and atherogenic lipid fractions in relation to the degree of urinary albumin excretion in type 2 diabetes mellitus. Nephron 1994;66:273-7.
21. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Envoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 1989;32:219-26.
22. Blackburn H, Keys A, Simonson E, Rautahaiju P, Punsar S. The electrocardiogram in populalion studies: a classification system. Circulation 1960;21:1160-75.
23. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp (a) glycoprotein phenotypes. Inheritance and relation to Lp (a)-lipoprotein concentrations in plasma. J Clin Invest 1987; 80:458-65.
24. Utermann G, Weber W. Protein composition of Lp (a) lipoprotein from human plasma. FEBS Lett 1983;154:357-61.
25. McLean JW, Tomlison JE, Kuang W-J et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987;300:132-7.
26. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein (a) gene accounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations. J Clin Invest 1992;90:52-60.
27. Hoff HF, Beck GJ, Skibinski CI, Jürgens G, O'Neil K, Kramer J. Serum Lp (a) levels as a predictor of vein graft stenosis after coronary artery by-pass surgery in patients. Circulation 1988;77: 1238-44.
28. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9:593-603.
29. Mogensen CA, Vestbo E, Poulsen PL et al. Microalbuminuria and potential confounders. Diabetes Care 1995;18:572-81.
30. McConathy WJ, Trieu VN, Koren E, Wang Ch, Corder C. Triglyceride-rich lipoprotein interactions with Lp (a). Chem Phys Lipids 1994;67/68:105-13.
31. Maioli M, Tonolo G, Pacífico A et al. Raised serum apolipoprotein (a) in active diabetic retinopathy. Diabetologia 1993;36:88-90.
32. Karadi I, Romies L, Palos G et al. Lp (a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin Chem 1989;35:2121-3.
33. Short CD, Durrington PN. Hyperlipidaemia and renal disease. Baillieres Clin Endocrinol Metab 1990;4:777-806.
34. Kasiski BL, O'Donnell MP, Cowardin W, Keane WF. Lipids and the kidney. Hypertension 1990;15:443-50.
35. Coritsidis G, Rifici V, Gupta S, Rie J, Shan Z, Neugarten J. Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int 1991;39:858-66.
36. Sato H, Suzuki S, Ueno M et al. Localization of apolipoprotein (a) and B-100 in various renal diseases. Kidney Int 1993;43:430-5.
37. Krämer-Guth A, Greiber S, Pavenstädt H et al. Interaction of native and oxidized lipoprotein (a) with human mesangial cells and matrix. Kidney Int 1996;49:1250-61.
38. Ramaswamy C, Staedman R, Jordan N, Westwick J, Williams JD. Lipoprotein (a) stimulates leukocyte adherence to endothelial cells in vitro (abstract). J Am Soc Nephrol 1995;6:907.
39. Sugiyama H, Kashihara T, Sekikawa Y et al. Cell-matrix interactions modulate cell apoptosis (abstract). J Am Soc Nephrol 1995;6:912.
40. Hervio L, Chapman M, Thillet J, Loyau S, Anglés-Cano E. Does apolipoprotein (a) heterogeneity influente lipoprotein (a) effects on fibrinolysis?. Blood 1993;82:392-7.
41. Leerink CB, Duif PFCCM, Verhoeven N et al. Apolipoprotein (a) isoform size influences binding of lipoprotein (a) to plasminmodified des-AA-fibrinogen. Fibrinolysis 1994;8:214-30.
42. Marcovina SM, Zhang ZH, Gaur VP, Albers JJ. Identification of 34 apolipoprotein (a) isoforms: differential expression of apolipoprotein (a) alleles between American blacks and whites. Biochem Biophys Res Commun 1993;191:1192-6.
43. White AL, Hixson JE, Rainwater DL, Lanford RE. Molecular basis for 'null' lipoprotein (a) phenotypes and the influence of apolipoprotein (a) size on plasma lipoprotein (a) level in the baboon. J Biol Chem 1994;25:9060-6.
44. Klausen IC, Berg Schmidt H, Lervang HH, Gerdes LU, Ditzel J, Fuergeman O. Normal lipoprotein (a) concentration and apolipoprotein (a) isoforms in patients with insulin- dependent diabetes mellitus. Eur J Clin Invest 1992;22:538-41.
45. Vassalli JD, Pepper MS. Membrane proteases in focus. Nature 1994;370:14-15.
46. Baricos WH, Cortez SL, el-Dahr SS, Schnaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA/ plasmin/MMP-2 cascade. Kidney Int 1995;47:1039-17.
47. Gaw A, Boerwinkle E, Cohen JC, Hobbs HH. Comparative analysis of the apo (a) gene, apo (a) glycoprotein, and plasma concentrations of Lp (a) in three ethnic groups. Evidence for no common 'null' allele in the apo (a) locus. J Clin Invest 1994;93: 2526-34.
48. Geroldi D, Bellotti V, Buscaglia P et al. Characterization of apo (a) polymorphism by a modified immunoblotting technique in an Italian population sample. Clin Chim Acta 1993;221:159-69.
49. Császár A, Dieplinger H, Sandholzer C et al. Plasma lipoprotein (a) concentration and phenotypes in diabetes mellitus. Diabetologia 1993;36:47-51.
50. Gruden G, Cavallo-Perin P, Olivetti C et al. Albumin excretion rate levels in non-diabetic offspring of NIDDM patients with and without nephropathy. Diabetologia 1995;38:1218-22.
51. Krolewski AS, Canessa M, Warram JH et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Mod 1988;18:140-5.
52. Cambien F, Poirier O, Lecerg L et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-4.
53. Forsblom CM, Eriksson JG, Ekstrand AV, Teppo AM, Taskinen MR, Groop LC. Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM. Diabetologia 1995;38:363-9.
54. Deckert T, Kofoed-Enevoldsen A, Norgaard K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen T. Microalbuminuria. Implications for micro- and macrovascular disease. Diabetes Care 1992;15: 1181-91.